Navigation Links
SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS
Date:2/12/2009

Recent Accomplishments & 2008 Highlights Include:

- Initiation of development activities to support regulatory filings for new Bitter Blockers

- Receipt of GRAS (Generally Recognized As Safe) designation for Sucralose Enhancer S2383, which allows commercialization in the U.S. and elsewhere

- New commercialization agreement for S2383 with Firmenich SA

- Continued activities to support regulatory filings for Sucrose (table sugar) Enhancer S6973

SAN DIEGO, CA, February 12, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX), a company focused on using proprietary taste receptor-based technologies to discover novel flavor ingredients for the food, beverage, and ingredient supply industries, today reported financial results for the fourth quarter and year ended December 31, 2008. Senomyx ended 2008 with more than $40 million in cash, cash equivalents, and investments available-for-sale and no debt.

"2008 was an important year for Senomyx, with both scientific and business accomplishments that culminated in the receipt of a GRAS (Generally Recognized As Safe) designation for our sucralose enhancer, S2383, and a new collaboration with Firmenich for the commercialization of S2383 in the US and elsewhere," said Kent Snyder, President and Chief Executive Officer of the Company. "Sucralose is a widely used high-intensity sweetener and we believe Firmenich has the ability to drive worldwide market acceptance and maximize the long-term revenue potential for S2383.

"Senomyx's progress in our Sweet Enhancer, Salt Enhancer, and Bitter Blocker programs during 2008 led to the extension and/or expansion of all the collaborative agreements that were due for renewal, as well as milestone payments from two partners," Snyder noted. "We also repor
'/>"/>

SOURCE Senomyx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW BITTER BLOCKERS
2. SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009
3. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 11TH ANNUAL NEEDHAM GROWTH STOCK CONFERENCE
4. SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE
5. SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS
6. SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY
7. SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008
8. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
9. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE WACHOVIA CONSUMER GROWTH CONFERENCE
10. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
11. SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , ... July 01, 2015 , ... Apex Therapeutics announced ... International Convention in Philadelphia, PA. , The presentation took place on Tuesday, ... the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... 2015 R-Japan Co.,Ltd. obtained the license of cell ... Medicine from the Ministry of Health, Labour and Welfare Kinki ... The fact that R- Japan ... from Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, ... provide stem cell manufacturing service to medical institutions. As of ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... a webinar to provide advanced scientific research into new classes of Nanoscale Graphene-based ... energy. Touted as 'the wonder material of the 21st Century' by the ...
(Date:6/30/2015)... Americord Registry, one of the fastest growing cord blood banks ... at Kirkland & Ellis LLP, as the newest member of ...   "We are thrilled about Andrew Horne,s ... , CEO of Americord. "He brings a wealth of knowledge ... growth and vision." Andrew Horne is ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Americord Registry Announces Andrew Horne as Advisory Board Member 2
... to be Indicated ... for Use in First-Line Therapy, SEATTLE, ... announced today that it has submitted a supplemental,Biologics License Application ... of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as,consolidation therapy after remission induction in ...
... Inc.,(NYSE: FRX ), an international manufacturer and ... Second Quarter financial results,before the U.S. stock market ... at 10:00 AM EDT, Forest will host a ... Operating Officer and Frank Perier, Senior,Vice President-Finance and ...
... 1 SpectraScience, Inc. (OTC,Bulletin Board: SCIE), a ... has shipped its non-invasive WavSTAT(R) Optical Biopsy,System to ... clinical,value of the Optical Biopsy System as an ... or cancer in the esophagus.,This marks the final ...
Cached Biology Technology:Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings 2University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia 2University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia 3University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia 4
(Date:6/23/2015)... , June 23, 2015   MedNet Solutions ... supports the entire spectrum of clinical research, is ... ™ , the company,s intuitive, flexible and ... a Silver 2015 Stevie® Award by the ... & Services Website category.  The American Business Awards ...
(Date:6/18/2015)... 2015 This report analyzes the worldwide markets ... Product Segments, which includes Immunoassay Analyzers and Reagents: Enzyme ... Immunoassay Systems, and Nephelometric Immunoassay Systems. The report provides ... , Japan , ... Latin America , and Rest of World. ...
(Date:6/17/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that Xiaomi, one of the world,s largest mobile ... ® family of capacitive touchscreen solutions and ... for its latest smartphones, the Xiaomi Mi Note ... in-cell display solutions and DDICs in discrete display ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
... the McKnight Brain Institute of the University of Florida ... other diseases by plundering the secrets of regeneration from ... newts, starfish and flatworms. , Fueled by about $6 ... funds, "The Regeneration Project" will connect scientists who work ...
... how different species use common genes to control their ... to accommodate their own features. The findings, which were ... Small’s laboratories in NYU’s Center for Developmental Genetics, offer ... species. The study is published in the latest issue ...
... medical practice that an antiretroviral drug widely used to treat ... own in patients co-infected with HIV. Their findings demonstrate ... drugs used to treat the AIDS virus. , "Our results ... has been shown to be active against HIV - it ...
Cached Biology News:Research project tackles 'regeneration' gap 2Research project tackles 'regeneration' gap 3NYU scientists identify how development of different species uses same genes with distinct features 2Widely used hepatitis B drug spurs HIV drug resistance 2Widely used hepatitis B drug spurs HIV drug resistance 3
... is the most thoroughly characterized enzyme available ... its overall utility and efficacy. , Its ... PCR applications. , It is QC ... AmpliTaq DNA Polymerase is a 94 kDa ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... DNA Polymerase is a versatile and easy-to ... PCR applications. GCpro Taq DNA Polymerase is ... E. coli, containing the DNA polymerase I ... a highly processive 5'-3' DNA polymerase activity. ...
Aspergillus (IgG) Ab EIA Sample Size: 100 l...
Biology Products: